WebAug 13, 2009 · Jennerex’s therapeutic approach is markedly different from gene therapy and standard cancer vaccine approaches. Jennerex Biotherapeutics was established in San Francisco CA and in Ottawa Canada in 2006 with Dr. David Kirn (CEO) in San Francisco and Dr. John Bell (CSO) from the Ottawa Health Research Institute/University of Ottawa. WebPrior to Aduro, Dr. Moon was a founding member of Jennerex Biotherapeutics (acquired by SillaJen in 2014) where she served as VP, Product Development, with responsibilities that …
丁香园-细胞基因技术（CGT）产业报告-2024.9-52页_凡人图书 …
Jennerex Biotherapeutics, Inc. (now owned by SillaJen) was an American private biopharmaceutical company that developed the oncolytic viruses JX-594 and JX-929 among others. By creating oncolytic viruses that can (1) kill tumor cells directly through lysis, (2) activate the immune system by delivering genes … See more Jennerex received its name in honor of Edward Jenner, the pioneer of the smallpox vaccine and "the father of immunology". Locations Headquarters are located in the Financial District, San Francisco See more 2003. Jennerex, Inc. (San Francisco, USA) was established. 2007. Jennerex completed Pexa-Vec Phase 1 clinical trial (HEP001). 2008. Jennerex initiated Pexa-Vec Phase 2a clinical trial (HEP007). 2009. See more • JX-594 See more • Jennerex homepage See more Oncolytic viruses developed by Jennerex are based on the vaccinia virus. Pexa-Vec (Jx-594) Pexa-Vec is an … See more Jennerex has partnered with Transgene, Green Cross, Lee's Pharmaceuticals, Rex Medical, and SillaJen for JX-594 development and … See more WebPrior to joining Tobira, Chris served as vice president, finance and corporate development of Jennerex Biotherapeutics. Prior to Jennerex, Chris held various positions at Onyx Pharmaceuticals, Inc. (now Amgen Inc.), including corporate strategy, marketing, product lifecycle management, and financial planning. Prior to Onyx, Chris provided ... sick monkeys youtube
Systemic Efficacy with Oncolytic Virus Therapeutics: Clinical Proof …
WebMay 8, 2013 · Jennerex Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products ... WebSep 3, 2013 · Jennerex Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of groundbreaking oncolytic … WebJames has over 20 years of preclinical and clinical experience in the field of gene and immunotherapy. James was previously CMO at Turnstone Biologics and Jennerex Biotherapeutics / SillaJen where he oversaw global clinical development for oncolytic virus therapies. Prior to Jennerex, he was Associate Director of Clinical Research at Cell Genesys. the phrase in turn